Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer
Groen, Veerle H.; Haustermans, Karin; Pos, Floris J.; Draulans, Cédric; Isebaert, Sofie; Monninkhof, Evelyn M.; Smeenk, Robert J.; Kunze-Busch, Martina; de Boer, Johannes C.J.; van der Voort van Zijp, Jochem; Kerkmeijer, Linda G.W.; van der Heide, Uulke A.
(2022) European Urology, volume 82, issue 3, pp. 252 - 257
(Article)
Abstract
Background: Focal dose escalation in external beam radiotherapy (EBRT) showed an increase in 5-yr biochemical disease-free survival in the Focal Lesion Ablative Microboost in Prostate Cancer (FLAME) trial. Objective: To analyze the effect of a focal boost to intraprostatic lesions on local failure–free survival (LFS) and regional + distant metastasis–free
... read more
survival (rdMFS). Design, setting, and participants: Patients with intermediate- or high-risk localized prostate cancer were included in FLAME, a phase 3, multicenter, randomized controlled trial. Intervention: Standard treatment of 77 Gy to the entire prostate in 35 fractions was compared to an additional boost to the macroscopic tumor of up to 95 Gy during EBRT. Outcome measurements and statistical analysis: LFS and rdMFS, measured via any type of imaging, were compared between the treatment arms using Kaplan-Meier and Cox regression analyses. Dose-response curves were created for local failure (LF) and regional + distant metastatic failure (rdMF) using logistic regression. Results and limitations: A total of 571 patients were included in the FLAME trial. Over median follow-up of 72 mo (interquartile range 58–86), focal boosting decreased LF (hazard ratio [HR] 0.33, 95% confidence interval [CI] 0.14–0.78) and rdMF (HR 0.58, 95% CI 0.35–0.93). Dose-response curves showed that a greater dose to the tumor resulted in lower LF and rdMF rates. Conclusions: A clear dose-response relation for LF and rdMF was observed, suggesting that adequate focal dose escalation to intraprostatic lesions prevents undertreatment of the primary tumor, resulting in an improvement rdMF. Patient summary: Radiotherapy is a treatment option for high-risk prostate cancer. The FLAME trial has shown that a high dose specifically targeted at the tumor within the prostate will result in better disease outcome, with less likelihood of regional and distant disease spread. The FLAME trial is registered on ClinicalTrials.gov as NCT01168479.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Dose-response analysis, External beam radiotherapy, Focal boosting, Patterns of failure analysis, Prostate cancer, Radiotherapy Dosage, Disease-Free Survival, Humans, Brachytherapy/methods, Proportional Hazards Models, Prostatic Neoplasms/pathology, Male, Urology, Research Support, Non-U.S. Gov't, Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Journal Article
ISSN: 0302-2838
Publisher: Elsevier
Note: Funding Information: Funding/Support and role of the sponsor: This study was supported by the Dutch Cancer Society (grant no. KWF 10088). The sponsor played no direct role in the study. Publisher Copyright: © 2021 European Association of Urology Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.
(Peer reviewed)